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Cost-effective and robust 
genotyping using double-mismatch 
allele-specific quantitative PCR
Steve Lefever  1,3,4, Ali Rihani  1,6, Joni Van der Meulen1, Filip pattyn  1,7, Tom Van 
Maerken1,3, Jo Van Dorpe5, Jan Hellemans2 & Jo Vandesompele  1,2,3,4
For a wide range of diseases, SNPs in the genome are the underlying mechanism of dysfunction. 
Therefore, targeted detection of these variations is of high importance for early diagnosis and (familial) 
screenings. While allele-specific PCR has been around for many years, its adoption for SNP genotyping 
or somatic mutation detection has been hampered by its low discriminating power and high costs. To 
tackle this, we developed a cost-effective qPCR based method, able to detect SNPs in a robust and 
specific manner. This study describes how to combine the basic principles of allele-specific PCR (the 
combination of a wild type and variant primer) with the straightforward readout of DNA-binding dye 
based qPCR technology. To enhance the robustness and discriminating power, an artificial mismatch 
in the allele-specific primer was introduced. The resulting method, called double-mismatch allele-
specific qPCR (DMAS-qPCR), was successfully validated using 12 SNPs and 15 clinically relevant somatic 
mutations on 48 cancer cell lines. It is easy to use, does not require labeled probes and is characterized 
by high analytical sensitivity and specificity. DMAS-qPCR comes with a complimentary online assay 
design tool, available for the whole scientific community, enabling researchers to design custom assays 
and implement those as a diagnostic test.
Various methods are available for single nucleotide polymorphism (SNP) genotyping, each with their bene-
fits and limitations. While SNP genotyping on a genome-scale is currently dominated by microarray analysis 
or massively parallel sequencing, assessment of a targeted selection of SNPs (or single nucleotide variants) is 
mainly done through PCR. Restriction fragment length polymorphism (RFLP)1 is possibly the oldest and sim-
plest method of this type relying on restriction digest followed by size separation of the differential fragments. 
PCR based methods, including high-resolution melting (HRM)2,3 and real-time PCR using hydrolysis probes4 
are faster and less laborious. Although these PCR based methods can be performed in high-throughput, are 
amenable to automation, and generate data that is relatively easy to analyze, a major drawback is the dependency 
on probes – either labeled or not – increasing design complexity and cost, especially when the number of sam-
ples to be genotyped is low. As an alternative, we present a cost-effective quantitative PCR (qPCR) based geno-
typing assay consisting of two parallel qPCR reactions, each including a modified allele-specific (AS) forward 
and common wild-type (WT) reverse primer (or vice versa). The combined information of quantification cycle 
values (Cq) from the two allele-specific reactions enables robust and straightforward genotyping. The simple 
setup avoids the necessity for probes, dedicated software and specialized instrumentation (and accompanying 
software) such as a high-resolution melting or sequencing instrument. Our method gives accurate genotyping 
results with all types of SNPs across a wide range of DNA input concentrations. Allele-specific qPCR assay 
design is available through our in-house developed primerXL web tool (www.primerxl.org) to increase adoption 
throughout the community.
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Methods
Primer and template design. SNP (or mutation) specific qPCR assays were designed using our in-house 
developed primerXL web tool (www.primerxl.org). An assay consists of one common reverse primer and two 
or more allele-specific (AS) forward primers with their 3′ end (position 0, Fig. 1) overlapping the SNP. Unless 
stated otherwise, an additional mismatch at position 3 (i.e. the fourth nucleotide from the primer 3′ end) was 
introduced to create double-mismatch AS primers (DMAS primers) and increase genotype discrimination power. 
By definition, each DMAS primer is referred to as a ‘match’ for the corresponding allele, and a ‘mismatch’ for the 
alternative allele. A custom Primer35 and UNAfold6 based perl script was used to generate 60 bp synthetic tem-
plates corresponding to the alleles and to be used as positive control templates. If possible, templates were kept 
free of secondary structures.
Cell cultures. Cell lines where cultured in RPMI medium, enriched with 10% fetal calf serum (FCS). All cell 
lines are regularly genotyped to confirm their identity and tested for mycoplasma contamination. The cell lines 
were obtained between 1993 and 2010 from Peter Ambros (STA-NB-12, STA-NB-3, STA-NB-8, STA-NB-9, and 
STA-NB-10), Garrett Brodeur (NGP, NLF, and NMB), Susan Cohn (NBL-S, SHEP), Valérie Combaret (CLB-GA), 
Thomas Look (SJNB-1, SJNB-8, and SJNB-10), John Lunec (SK-N-BE, SK-N-BE(2c)), Sven Påhlman (SH-SY5Y), 
Patrick Reynolds (CHP-134, CHP-901, CHP-902R, SMS-KAN, and SMS-KCNR), and Rogier Versteeg (GICIN-1, 
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Figure 1. Schematic representation of DMAS-qPCR results for one assay on one representative homozygous 
AA sample (sample X - top panel, qPCR amplification curves) and 75 samples (one third homozygous AA, 
heterozygous AB and homozygous BB) as scatter (middle) and difference plots (bottom).
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IMR-32, LA-N-1, LA-N-2, LA-N-5, LA-N-6, N-206, SK-N-AS, SK-N-FI, SK-N-SH, and TR-14), or established in 
our laboratory (UHG-NP).
Single mismatch reactions. AS assays (without additional mismatch) were designed for 6 SNPs involved 
in the TP53 pathway. qPCR was performed in duplicate on a LightCycler480 (Roche) instrument. For assay vali-
dation, two homozygous (one for each allele) and one heterozygous (1:1 mix of the two templates) synthetic sam-
ple consisting of 10 000 template molecules were assessed. For all synthetic samples, a 6-point 10-fold standard 
curve using perfect matching forward and reverse primers was run. All 5 µl qPCR reactions were performed using 
the Bio-Rad SsoAdvanced SYBR Green Supermix, according to the manufacturer’s recommendations with a final 
primer concentration of 0.25 µM and 2 µL template input (2 min at 95 °C; 44 cycles of 5 s at 95 °C and 30 s at 60 °C).
Determination of optimal artificial mismatch position. AS assays harboring all possible nucleotides 
at positions 1 to 5 were designed for 6 SNPs involved in the TP53 pathway (Table 1). qPCR was performed in 
duplicate on a LightCycler480 (Roche) instrument. For assay validation, two homozygous (one for each allele) 
and one heterozygous (1:1 mix of the two templates) synthetic sample consisting of 10 000 template molecules 
were assessed. For all synthetic samples, a 6-point 10-fold standard curve using perfect matching forward and 
reverse primers was run. All 5 µl qPCR reactions were performed using the Bio-Rad SsoAdvanced SYBR Green 
Supermix, according to the manufacturer’s recommendations with a final primer concentration of 0.25 µM and 
2 µL template input (2 min at 95 °C; 44 cycles of 5 s at 95 °C and 30 s at 60 °C).
allele forward reverse template
rs6734469 A/G TCCCCCACTGATTTCTTCTGTAC[A/C/G/T] ACTGTCAGCACCAGAGGGAC TCCCCCACTGATTTCTTCTGTAC[A/G]AGATACTCTACTCTGGGTCCCTCTGGTGCTGACAGT
rs187115 C/T CAGCGAGATAGTTGTGCTGACA GAGTGAGAAAGATGTTATCATC GTCATTG[A/C/G/T]
CAGCGAGATAGTTGTGCTGACAGTCATATA[C/T]
CAATGACGATGATAACATCTTTCTCACTC
rs1027154 C/G CTCCATACACTTTCTTAGGTGACTTTT[A/C/G/T] ACCAGAGCATTCACCCTCAG CTCCATACACTTTCTTAGGTGACTTTT[C/G]CGAAGTGAACCACTGAGGGTGAATGCTCTGGT
rs2168945 A/C GGAATAGGAAATGTGATGCAAGCAGA[A/C/G/T] TTGAATAGGGCAACGACAGATGA GGAATAGGAAATGTGATGCAAGCAGA[A/C]CAGGTTTACGTCATCTGTCGTTGCCCTATTCAA
rs4245739 A/C GAGAAAAGACCACGAGACGG TTTTCAAATAATGTGGTAA GTGAAC[A/C/G/T]
GAGAAAAGACCACGAGACGGAGACTGATTTG 
GCC[A/C]GTTCACTTACCACATTATTTGAAAA
rs2273953 A/G TTCCTTCCTTCCTGCAGAGC[A/C/G/T] AGAGCTCCAGAGGTGCTCAAA TTCCTTCCTTCCTGCAGAGC[A/G]AAGAATTCACTGTGACTATTTGAGCACCTCTGGAGCTCT
Table 1. SNPs and their corresponding oligonucleotide sequences. Mismatches and allele-specific nucleotides 
are marked bold and underlined.
allele forward reverse template
rs6734469 A/G TCCCCCACTGATTTCTTCTGCAC[A/G] ACTGTCAGCACCAGAGGGAC TCCCCCACTGATTTCTTCTGTAC[A/G]AGATACTCTACTCTGGGTCCCTCTGGTGCTGACAGT
rs187115 C/T CAGCGAGATAGTTGTGCTGACA GAGTGAGAAAGATGTTATCAT CGTCACTG[A/G]
CAGCGAGATAGTTGTGCTGACAGTCATATA[C/T]
CAATGACGATGATAACATCTTTCTCACTC
rs1027154 C/G CTCCATACACTTTCTTAGGTGACTCTT[C/G] ACCAGAGCATTCACCCTCAG CTCCATACACTTTCTTAGGTGACTTTT[C/G]CGAAGTGAACCACTGAGGGTGAATGCTCTGGT
rs2168945 A/C GGAATAGGAAATGTGATGCAAGCCGA[A/C] TTGAATAGGGCAACGACAGATGA GGAATAGGAAATGTGATGCAAGCAGA[A/C]CAGGTTTACGTCATCTGTCGTTGCCCTATTCAA
rs4245739 A/C GAGAAAAGACCACGAGACGG TTTTCAAATAATGTGGT AAGTGCAC[G/T]
GAGAAAAGACCACGAGACGGAGACTGAT 
TTGGCC[A/C]GTTCACTTACCACATTATTTGAAAA
rs2273953 A/G TTCCTTCCTTCCTGCAGCGC[A/G] AGAGCTCCAGAGGTGCTCAAA TTCCTTCCTTCCTGCAGAGC[A/G]AAGAATTC ACTGTGACTATTTGAGCACCTCTGGAGCTCT
rs319227 G/T CCCTGCTCTAGAACATCGACCTA[A/C] GCAGACCCAGGACTTGAATGC CCCTGCTCTAGAACATCGACATA[A/C]GTGTAC CCTGTATTGGCATTCAAGTCCTGGGTCTGC
rs2069347 C/T CATATTTTAGTCCTCGGTATCT AACAAAG[T/C] ATGACTTGTACATAAGAGCAACGATCT
CATATTTTAGTCCTCGGTATCTAACACAG[C/T]
CTGAGATCGTTGCTCTTATGTACAAGTCAT
rs2426127 C/T GGCTGACAGAATTCCTTTTTAGATGC CCAAAGACCCTTAGCCCTAAATC[A/G] GGCTGACAGAATTCCTTTTTAGATGCGAGT GCTCCG[C/T]GAGTTAGGGCTAAGGGTCTTTGG
rs1800054 C/G ATTAAACATCTAGATCGGCAT TCAGCTT[C/G]
TGCAAGGCATAATGATA 
TATAGGAAGCAA
ATTAAACATCTAGATCGGCATTCAGATT[C/G]
CATTGCTTCCTATATATCATTATGCCTTGCA
rs34330 C/T CGTCGGGGTCTGTGTCTTTTG AACAAAGCGCCCCTAAGC[A/G] CGTCGGGGTCTGTGTCTTTTGCGGGGGGA GGGATCGAAATA[C/T]GCGTAGGGGCGCTTTGTT
rs1045485 C/G TGCTCTCCAGCTGTGGTCTG AGATTTGCTCTACTGTGCAGTAAT[C/G] TGCTCTCCAGCTGTGGTCTGCTACAACTG GTAGGT[C/G]ATGACTGCACAGTAGAGCAAATCT
Table 2. SNPs and their corresponding oligonucleotide sequences. Mismatches and allele-specific nucleotides 
are marked bold and underlined. The first 6 SNP assays were used for the determination of the optimal artificial 
mismatch location, assessment of the required DNA input concentration and assay specificity. The latter 6 SNP 
assays were only applied in the assay specificity and DNA input concentration experiments.
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Effect of input concentration. DMAS-qPCR assays were designed for the SNPs used in the single mis-
match experiment, and 6 additional SNPs involved in the same pathway (Table 2). A 4-point, 4-fold dilution series 
(16, 4, 1 and 0.25 ng was created for eight tumor cell lines (SJNB-8, CHP-901, SHEP, SJNB-6, GIMEN, CHP-134, 
N-206 and SH-SY5Y). PCR reactions were performed as described earlier on a LightCycler480 (Roche) instru-
ment: two parallel qPCR reactions, each with a different allele-specific forward primer and a common reverse 
primer.
Assessment of relative analytical sensitivity. DMAS-qPCR assays were designed for 15 clinically rel-
evant mutations (Table 3). For each of the 48 selected tumor cell lines (ACN, CHLA-90, CHP-134, CHP-901, 
CHP-902R, CLB-GA, GICIN-1, GIMEN, IMR-32, Kelly, LA-N-1, LA-N-6, LA-N-6 (T10-295), LA-N-2, LA-N-5, 
N-206, NB-1, NB-13, NB-5, NBL-S, NGP, NLF, NMB, SH-SY5Y, SH-EP, SJNB-10, SJNB-12, SJNB-6, SJNB-8, 
SJNB-1, SK-N-AS, SK-NF-I, SK-MYC2, SK-NB-E, SK-N-BE(2c), SKNSH, SMS-KAN, SMS-KCN, SMS-KCNR, 
STA-NB-10, STA-NB-12, STA-NB-3, STA-NB-8, STA-NB-9, TR-14, UHG-NP and UKF-NB3), 4 ng DNA input 
was subjected to each of the DMAS-qPCR assays with a final primer concentration of 0.25 µM per 5 µL reaction. 
In addition, the sensitivity of these assays was tested using synthetic templates. For this, a 14-point, 2-fold muta-
tion in wild-type – and vice versa – dilution series was created (mutation/WT: 50/50, 25/75, 12.5/87.5, 6.25/93.75, 
3.13/96.87, 1.56/98.44, 0.78/99.22, 0.39/99.61, 0.20/99.80, 0.10/99.90, 0.05/99.95, 0.025/99.975, 0.013/99.987, 
0/100), followed by qPCR on a LightCycler 480 (Roche) instrument using a total of 100 000 input molecules per 
5 µL reaction and a final primer concentration of 0.25 µM.
Hydrolysis probe based qPCR assays. Assays were performed using the TaqMan SNP Genotyping mas-
termix with 0.125 µL of the 40x SNP genotyping assay and 9.5 ng input DNA in a 5 µl reaction on a 7900HT 
(Applied Biosystems) instrument (Table 4). The following protocol was used: 2 min at 50 °C; 10 min at 95 °C; 40 
cycles of 15 s at 95 °C and 60 s at 60 °C.
allele allele-specific primers common primer
rs113488022 BRAF (V600E) A/T AATAGGTGATTTTGGTCTAGCTACAG[A/T] GTAACTCAGCAGCATCTCAGGG
rs113993960 CF (deltaF508) C/T GCCTGGCACCATTAAAGAAAATATCAT[C/T] GGCATGCTTTGATGACGCTTC
rs6025 Leiden mutation (FCTRV) C/T ACTTCAAGGACAAAATACCTGTATTCCT[C/T] TCGCCTCTGGGCTAATAGGAC
rs77375493 JAK2 (V617F) A/C AGTTTTACTTACTCTCGTCTCCACAGA[A/C] AGCAGCAAGTATGATGAGCAAGC
COSM28057 ALK (F1174L_A > G) C/T CCTCTCTGCTCTGCAGCAAA[C/T] GGGTCTCTCGGAGGAAGGAC
COSM28059 ALK (F1174C) A/G CCTCTCTGCTCTGCAGCAAAT[G/T] GGGTCTCTCGGAGGAAGGAC
COSM28055 ALK (F1174L_G > T) A/C CTCTCTGCTCTGCAGCAAATT[A/C] GGGTCTCTCGGAGGAAGGAC
COSM28056 ALK (R1275Q) C/T CAGTCTTTACTCACCTGTAGATGTCT[C/T] GCCAGAAACTGCCTCTTGACC
rs17851045 KRAS (codon 61) A/T CCCTCATTGCACTGTACTCCTC[A/T] TTGTCCGTCATCTTTGGAGCAG
COSM12429 EGFR (L858R) G/T TGTCAAGATCACAGATTTTGGGC[G/T] CTAGTGGGAAGGCAGCCTGG
COSM6252 EGFR (G719S) A/G ACTGAATTCAAAAAGATCAAAGTGCTG[A/G] AGACCATGAGAGGCCCTGC
COSM6253 EGFR (G719C_G > T) G/T ACTGAATTCAAAAAGATCAAAGTGCTG[G/T] AGACCATGAGAGGCCCTGC
COSM18441 EGFR (G719C_GG > TT) A/C GAACGCACCGGAGCC[A/C] TGGAGCCTCTTACACCCAGTG
COSM6239 EGFR (G719A) C/G TGAATTCAAAAAGATCAAAGTGCTGG[C/G] GCTCCCCACCAGACCATGAG
COSM6240 EGFR (T790M) C/T CCACCGTGCAGCTCATCA[C/T] AGCAGGTACTGGGAGCCAAT
Table 3. Clinically relevant mutations and their corresponding oligonucleotide sequences. Mismatches and 
allele-specific nucleotides are marked bold and underlined.
Reference TaqMan assay ID
rs6734469 10 C__29724290_10
rs187115 10 C____779820_10
rs1027154 10 C___1935268_20
rs2168945 10 C___1673863_10
rs4245739 11 C__11623776_10
rs2273953 12 C__16180357_10
rs319227 10 C____803346_10
rs2069347 10 C___2000410_20
rs2426127 10 C__16230087_10
rs1800054 12 C___2283268_20
rs34330 12 C___2402292_10
rs1045485 12 C___8823877_20
Table 4. SNPs and their corresponding TaqMan assay IDs.
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FFPE DMAS-qPCR. FFPE-DNA was extracted from tumor lung biopsies by means of the QIAamp DNA 
FFPE Tissue kit (Qiagen) using three to five 8–10 µM sections. DMAS-qPCR reactions for three EGFR mutations 
(T790M, L858R and G719A) were performed on a LightCycler 480 instrument (Roche), using 16 ng input DNA 
per 5 µL reaction. Variant status was assessed using targeted resequencing on an Illumina MiSeq instrument 
(Nextera XT library prep, 2 × 250 cycles), followed by CLCbio Genomics Workbench (Qiagen) based variant 
calling. For all samples and mutations, variant allele frequencies (VAF) were determined using droplet digital 
PCR on a QX100 droplet generator/reader (Bio-Rad) using PrimePCR ddPCR mutation assays according to the 
manufacturer. All experimental protocols applied on the FFPE tumor samples were approved by the ethical com-
mittee of the University Hospital Ghent (project number 2004/094) and have been carried out in accordance with 
relevant guidelines and regulations. For each sample, informed consent was obtained from the corresponding 
patient or from a parent and/or legal guardian in case the patient was under 18 years old.
Results
Single mismatch AS-qPCR reactions. Allele-specific assays were designed for 6 SNPs involved in the 
TP53 pathway (Table 1) and tested on eight randomly selected and previously genotyped cancer cell line samples. 
For each sample and SNP, four parallel reactions were performed in duplicate, each with a different AS primer. In 
this experiment, the four possible nucleotides were used at the 3′ end of each AS primer - resulting in three single 
mismatch reactions and one perfect match reaction. These AS-qPCR results indicate that the discrimination 
power of a single 3′ terminal mismatch is not sufficient for reliable genotype calling (Suppl. Table 1). For only two 
SNPs (rs4245739 and rs1027154) a clear separation between the three genotypes was observed (data not shown).
Double mismatch AS-qPCR reactions (DMAS-qPCR). Based on previous work, inclusion of an arti-
ficial mismatch into the AS primer was evaluated in order to increase the genotype discrimination power7,8 
(Table 2). This results in a double mismatch when the AS primer for allele A hybridizes to allele B (called ‘mis-
match’, see Materials and Methods), and a single mismatch when primer A hybridizes to its target allele A (called 
‘match’). Although the artificial mismatch may have a beneficiary effect on limiting amplification of the ‘mis-
match’ reaction, the potential downside of this approach is that the artificial mismatch may negatively impact 
the ‘match’ reaction. To determine the optimal position of the mismatch in order to maximize the discrimination 
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Figure 2. (A) Violin plot denoting dCq differences and standard deviation per position, between match and 
mismatch allele-specific primer for homozygote samples (position 0 is terminal position), (B) Violin plot 
denoting Cq differences and standard deviation, per position between ‘perfect’ match reactions – harboring no 
3′ terminal mismatch – with and without artificial mismatch (position 0 is terminal position).
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power while minimizing the effect on the ‘matching’ AS primer, all possible nucleotide changes were incorpo-
rated into positions one to five of both AS primers and tested on synthetic template samples. Data for six SNPs 
presented in Fig. 2 indicate that mismatches on positions two and three result in the highest average dCq dif-
ferences (ddCq) (and thus highest discriminating power) between ‘match’ and ‘mismatch’ reactions (Fig. 2A). 
When taking into account the impact of the artificial mismatch on the match reaction (Fig. 2B) and the standard 
deviation of the dCq values, a mismatch on position three appears to be the optimal solution (low standard devia-
tion, limited effect on the match and large and reproducible dCq value between ‘match’ and ‘mismatch’ reaction). 
Assessment of the Cq scatterplots (Suppl. Fig. 1) leads to the same conclusion with clearest clustering of the three 
different genotypes for an artificial mismatch on position three. These plots also clearly show the expected Cq dif-
ference of one cycle between homozygote and heterozygote genotypes, underscoring the accuracy and quantita-
tive power of the assays. In addition to the position of the artificial mismatch, the mismatch type may in principle 
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Figure 3. Cq difference plots – one dimensional plots of the Cq difference between the perfect and mismatch 
reactions of the same assay – for 12 TP53 related SNPs in 8 neuroblastoma samples using 16, 4, 1 and 0.25 ng 
input DNA.
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also affect the resolution of the genotyping assays. Although further experiments may be needed, our results 
suggest that there are no differential effects when comparing different base pair mismatches on position three.
Effect of DNA input concentration. Assays for six additional SNPs (Table 2), also involved in the TP53 
pathway, were designed and tested on a serial dilution series (16, 4, 1 and 0.25 ng) of DNA samples from eight 
neuroblastoma cell lines to evaluate the robustness of the method with regard to the input concentration. While 
the data from the previous experiment suggested that the type of mismatch at position 3 had no specific effect, 
for the 6 new assays, the type of the artificial mismatch was chosen based on reported mismatch stability ranking: 
G/G > G/T ≥ G/A > T/T ≥ A/A > T/C ≥ A/C ≥ C/C (ranked from most stable to least stable mismatch)9. A Cq 
difference plot of the data (Fig. 3) demonstrates that in 98% (376/384) of the DNA sample-concentration com-
binations the correct genotype could be determined (using a 5 dCq cut-off). Although the discrimination power 
of the DMAS-qPCR assays decreases with lower concentrations of input DNA, the wide concentration range 
(64-fold, down to 0.25 ng input DNA or ~80 copies) at which the DMAS-qPCR assays are still able to discriminate 
between genotypes confirms the sensitivity and robustness of the method. Only for one SNP, namely rs34330, 
genotype calling becomes more challenging when using the lowest input concentration point.
Assay specificity. To determine the accuracy of our method, the 12 DMAS-qPCR genotyping assays were 
tested on DNA from 48 neuroblastoma cell lines (4 ng input) for which corresponding TaqMan results were avail-
able. All of the 576 genotypes could be called using our method with a manually set threshold (100% call rate), 
while 23 TaqMan reactions resulted in undetermined calls (96% call rate using the TaqMan Genotyper software) 
(Fig. 4 and Suppl. Table 2). For the remaining 553 genotypes, results were identical for 547 genotypes when com-
paring DMAS-qPCR and TaqMan qPCR (98.9% concordance). When recalling the TaqMan results manually, 
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the concordance increases to 99.5% (7 undetermined calls, 3 incorrect calls and 566 correct calls). In addition, 
the 48 neuroblastoma cell line cohort was subjected to DMAS-qPCR for 15 clinically relevant mutations (Fig. 5, 
Table 3). Genotype calling was performed identically to the TP53 SNPs. The results show that the majority of the 
cell lines are negative for the respective mutations, with the exception of the EGFR G719C GG> TT mutation, a 
BRAF V600E variant in the ACN cell line, two FCTRV (Leiden) mutations and a few ALK F1174L and R1275Q 
mutations. Comparison of the DMAS-qPCR calls for these two latter mutations with corresponding TaqMan 
results available for a subset of the cell lines (n = 40) again indicate a high concordance (98.75%) (Suppl. Table 3).
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Assay sensitivity for mutation detection. Since tumor samples are almost always contaminated with 
stromal cells, the sensitivity of any genotyping method has a large impact on calling accuracy. To assess the sensi-
tivity of our DMAS-qPCR approach, synthetic templates were developed for both the mutant and wild-type allele 
of each of the 15 clinically relevant mutations. A 14-point, 2-fold dilution of the mutant allele in a wild-type back-
ground – and vice versa – was then created followed by DMAS-qPCR using the corresponding assay. We observe 
that the dCq values deviate from the theoretical trend line for the higher target dilutions (Fig. 6). This can most 
likely be attributed to specificity of the assay since at very low mutant concentrations, the mutant primer will start 
competing with the wild-type primer to amplify the wild-type allele. Nevertheless, when using a conservative 2 
dCq difference to discriminate between wild-type and a mutant in wild-type sample, sensitivity scores ranging 
from 6.25% down to 0.05% (mutant in WT) can be reached without any optimization; nine of the 15 assays show 
detection sensitivities below 1%.
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Performance on FFPE tumor samples. Since DMAS-qPCR performance can differ significantly between 
a setup using cell lines (or synthetic templates) and real tumor samples – due to the more heterogeneous nature 
of the latter – the robustness of the technique was assessed on DNA isolated from FFPE lung tumor tissues with 
known EGFR T790M, L858R and G719A mutation status. Results show that all four EGFR L858R mutant and 
all three G719A mutant samples can easily be called using a 5 dCq cut-off, with the largest discriminating power 
(i.e. largest dCq values for homozygous wild-type samples) being observed for the L858R assay. For the T790M 
mutation, only one of the two mutant samples was called (Fig. 7). This can be attributed to both the suboptimal 
specificity of the wild-type assay and the low variant allele frequency of this particular sample. When plotting 
the ddPCR variant allele frequency in function of the DMAS dCq values, a very good correlation is observed, 
indicating that the results obtained through DMAS-qPCR reflect the genotype and variant allele frequency of the 
sample very well (Fig. 8).
Implementation in primerXL. The design of DMAS-qPCR genotyping assays has been implemented 
in our web tool primerXL to increase the usability of the method (www.primerxl.org). Design requests can be 
submitted using a reference SNP identification number (dbSNP rs ID), a sequence with the mutation annota-
tion between brackets or a chromosomal location accompanied by the WT and mutant allele(s). The mutation 
information – retrieved from the Ensembl server in case a rs number is submitted – is then fed into the design 
pipeline resulting in the generation of three primers: one common primer and two allele-specific primers. All 
assays undergo in silico specificity analysis and assessment of secondary structures in the primer annealing sites. 
Available Primer35 options such as annealing temperature, amplicon length and others parameters are also cus-
tomizable. The primerXL genotyping assay design success rate is 69.8% (624 out of 894 randomly selected SNPs 
using identical design settings), with 80.7% (218/270) of the failed SNPs located in repeats (according to Ensembl 
release 75). Design success rate can be increased by optimizing the design settings on a mutation specific basis. 
Currently, primerXL is only capable of designing assays for single nucleotide substitutions, but the same princi-
ples could also be applied to larger substitutions, insertions and deletions. This functionality will be implemented 
in future versions.
Discussion
Our study on the impact of primer-template mismatches on qPCR performance suggested novel options for 
design of a cost-efficient and straightforward method for SNP genotyping or mutation detection. Initial experi-
ments indicated that an artificial mismatch in the primer sequence needs to be introduced as a single mismatch 
at the 3′ end of the allele-specific primer does not have sufficient discriminative power. Additional tests showed 
that an artificial mismatch at the fourth nucleotide from the 3′ end of the allele-specific primer has the best 
overall performance, independent of the type of artificial mismatch. Genotyping of twelve SNPs involved in the 
TP53 pathway and 15 clinically relevant mutations on 48 neuroblastoma cell lines demonstrated high specificity, 
resolution and robustness of the assays. However, for rs34330 clustering of the different genotypes was less pro-
nounced which can be attributed to the higher Cq values of this assay compared to the others. The sensitivity of 
the assays in the context of WT/mutant hybrid samples ranges from 0.05 to 6.25%. However, we hypothesize that 
a small modification to the method – such as chemically modified allele-specific primers with higher binding 
affinities – could help increase overall sensitivity. Through automated instruments, DMAS-qPCR could be per-
formed in high-throughput contexts. However, for large sets of SNPs, the method is outperformed by MS-based 
genotyping both in the context of scalability and cost-efficiency. In comparison to other qPCR based genotyping 
methods such as hydrolysis probes and high-resolution melting curve analysis, DMAS-qPCR has the benefit 
that no probes or specialized instruments are needed. This results in a reduction of the reaction complexity and 
cost of the assay. Comparison of DMAS-qPCR genotype calling with TaqMan results for twelve SNPs in 48 cell 
lines and 2 clinically relevant mutations on 40 cell lines, showed a hundred percent calling success rate with 547 
correct calls out of 576 (98.9% concordance) genotypes and 79 correct calls out of 80 genotypes (98.75% con-
cordance), respectively. TaqMan assays resulted in approximately four percent undetermined calls, indicating a 
higher robustness for DMAS-qPCR genotyping assays. Possible limitations of our method include the difficulty 
to assess genotype status in difficult DNA regions (e.g. homologous or homopolymeric regions due to the limited 
assay design space) and the use of more input DNA since two parallel qPCR reactions must be performed for 
each SNP or mutation to be genotyped. However, the latter problem could be circumvented by reducing the DNA 
input amounts per reaction, as data have shown that even low DNA input amounts result in acceptable analytical 
sensitivities. An alternative but yet untested approach would entail the addition of a GC tail to one off the AS 
primers of a DMAS-qPCR assay, enabling genotype calling using a single reaction by means of melting curves 
instead of (d)Cq values. Also, to enable DMAS-qPCR based high-throughput genotype calling a classification 
or clustering method would be preferred instead of the cut-off based calling performed in this study. Finally, by 
utilizing synthetic templates, this study introduced the idea of using these molecules as positive controls for gen-
otyping reactions. Together with the user-friendly assay design in primerXL, our fast, simple and cost-effective 
qPCR based genotyping technique, combined with a new visualization and analysis method under the form of a 
difference plot, is a powerful alternative to the commonly used genotyping methods.
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